Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?
Crossref DOI link: https://doi.org/10.1038/nrurol.2017.127
Published Online: 2017-08-08
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Veccia, Antonello
Maines, Francesca
Caffo, Orazio
Text and Data Mining valid from 2017-08-08
Article History
First Online: 8 August 2017
Competing interests
: O.C. has received honoraria from Sanofi Aventis, Astellas and Janssen. The other authors declare no competing interests.